Abstract
DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) has proved to be an effective salvage therapy for refractory-relapsed MM patients. Little is known, however, about its potential as mobilizing therapy. The aim of this study was to evaluate the efficacy of DCEP in mobilizing PBSC and to define its toxicity. Fifty-five MM patients received DCEP followed by G-CSF as part of high-dose programs including autologous transplantation. At the time of mobilization, 40 patients had previously received VAD only, and 15 alkylating agents. Mobilization was successful (minimum number of CD34+ cells 2 × 106/kg) in 48/55 patients (87%), and 41/55 patients (75%) collected >4 × 106/kg CD34+ cells. Of the seven patients who did not mobilize stem cells, five (71%) had been previously exposed to alkylating agents. The median number of CD34+ cells harvested was 5.8 × 106/kg (range 2.1–22.4). There was no treatment-related mortality. The side-effects of DCEP were always tolerable. No neutropenia <1000/μl nor thrombocytopenia <50 000/μl were observed. No patient required transfusion as a consequence of therapy, or hospitalization for septic complications. In conclusion, DCEP, in addition to its demonstrated anti-tumor activity, is an effective regimen for mobilizing peripheral blood progenitor cells in myeloma patients, with little or no side-effects. These properties render DCEP a useful regimen for the debulking and mobilization phase of high-dose programs for multiple myeloma. Bone Marrow Transplantation (2001) 28, 835–839.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Attal M, Harousseau J-L, Stoppa AM et al. Prospective, randomised trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma New Engl J Med 1996 335: 91–97
Barlogie B, Jagannath S, Vesole D et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma Blood 1997 89: 789–793
Bensinger W, Appelbaum F, Rowley S et al. Factors that influence collection and engraftment of autologous peripheral blood stem cells J Clin Oncol 1995 13: 2547–2555
Scheid C, Draube A, Reiser M et al. Using at least 5 × 106/kg CD34+ cells for autologous stem cell transplantation significantly reduces febrile complications and use of antibiotics after transplantation Bone Marrow Transplant 1999 23: 1177–1181
Tricot G, Jagannath S, Vesole D et al. Peripheral blood stem cell transplant for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients Blood 1995 85: 588–596
Goldschmidt H, Hegenbart U, Haas R, Hunstein W . Mobilization of peripheral blood progenitor cells with high-dose cyclophosphamide (4 or 7 g/m2) and granulocyte colony-stimulating factor in patients with multiple myeloma Bone Marrow Transplant 1996 17: 691–697
Kotasek D, Shepherd KM, Sage RE et al. Factors affecting blood stem cells collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors Bone Marrow Transplant 1992 9: 11–17
To LB, Shepperd KM, Haylock DN et al. Single high doses of cyclophosphamide enable the collection of high numbers of haemopoietic stem cells from the peripheral blood Exp Hematol 1990 18: 442–447
Bensinger W, Buckner CD, Shannon DK et al. Transplantation of allogeneic CD34+ peripheral blood stem cells in patients with advanced hematologic malignancy Blood 1996 88: 4132–4138
Gorin NC, Lopez M, Laporte JP et al. Preparation and successful engraftment of purified CD34+ bone marrow progenitor cells in patients with non-Hodgkin lymphoma Blood 1995 85: 1647–1654
Schiller G, Vescio R, Freytes C et al. Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma Blood 1995 86: 390–397
Lemoli RM, Martinelli G, Zamagni E et al. Engraftment, clinical and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy Blood 2000 95: 2234–2239
Stockerl-Goldstein KE, Brown JM, O'Brian RM et al. Increased transplant-related mortality following high-dose sequential chemotherapy and autologous hematopoietic cell transplantation using the Ceprate SC stem cell concentration system for multiple myeloma Blood 1999 94: (Suppl. 1) 2704a
Bensinger WI . Should we purge? Bone Marrow Transplant 1998 21: 113–115
Stewart DA, Guo D, Morris D et al. Superior autologous blood stem cell mobilization from dose-intensive cyclophospamide, etoposide, cisplatin plus G-CSF than from less intensive chemotherapy regimens Bone Marrow Transplant 1999 23: 111–117
Cook G, Marinaki P, Farrell E et al. Peripheral blood progenitor cell mobilization in patients with multiple myeloma following oral idarubicin and dexamethasone (Z-Dex) induction therapy Leukemia 1997 11: (Suppl. 5) 35–40
Demirer T, Bukner CD, Storer B et al. The effect of different chemotherapy regimens on peripheral blood stem cell mobilization yield Proc Ann Meet Am Soc Oncol 1996 15: 1007a
Demirer T, Bukner CD, Gooley T et al. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma Bone Marrow Transplant 1996 17: 937–941
Desikan KR, Jagannath S, Siegel D et al. Dexamethasone, cyclophosphamide, etoposide and cis-platinum (DCEP), an effective regimen for relapse after high-dose chemotherapy and autologous transplantation Blood 1996 88: (Suppl. 1) 2331a
Munshi N, Desikan R, Anaissie E et al. Peripheral blood stem cell collection after CAD+ G-CSF as part of total therapy II in newly diagnosed multiple myeloma: influence of thalidomide administration Blood 1999 94: (Suppl. 1) 2577a
Desikan R, Munshi N, Zangari M et al. DCEP consolidation chemotherapy after 2 cycles of melphalan-based high-dose therapy. High incidence of CR and superior outcome in comparison with matched historical controls Blood 1999 94: (Suppl. 1) 1411a
Corso A, Caberlon S, Pagnucco G et al. Blood stem cell collection in multiple myeloma: definition of a scoring system Bone Marrow Transplant 2000 26: 283–286
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lazzarino, M., Corso, A., Barbarano, L. et al. DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma. Bone Marrow Transplant 28, 835–839 (2001). https://doi.org/10.1038/sj.bmt.1703240
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1703240
Keywords
This article is cited by
-
Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease
Journal of Hematology & Oncology (2022)
-
The VR-DCEP regimen rescues mobilization failures and controls refractory disease in multiple myeloma
Bone Marrow Transplantation (2020)
-
DCEP and bendamustine/prednisone as salvage therapy for quad- and penta-refractory multiple myeloma
Annals of Hematology (2020)
-
DCEP for relapsed or refractory multiple myeloma after therapy with novel agents
Annals of Hematology (2014)
-
Intracranial hemorrhage in adult patients with hematological malignancies
BMC Medicine (2012)